Kypha discovers, develops and commercializes innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. These tests have application across a wide range of indications that include: lupus, stroke, traumatic brain injury, preeclampsia, infection, nephrology/kidney disease and transplant rejection. Potential implications include detecting the onset of adverse events earlier and optimizing treatment sooner, predicting outcomes more accurately, and managing disease and patient more effectively.
Based on the ability to measure complement activation within the body, the company has developed a point of care platform called “COMP ACT” that delivers real time results to the physicians. Kypha has developed an extensive clinical collaborator network to support the clinical trials as well as the identification of new biomarkers across multiple indications.
Based on the ability to measure complement activation within the body, the company has developed a point of care platform called “COMP ACT” that delivers real time results to the physicians. Kypha has developed an extensive clinical collaborator network to support the clinical trials as well as the identification of new biomarkers across multiple indications.
Location: United States, Missouri, Saint Louis
Employees: 11-50
Total raised: $4M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Missouri T... | missourite... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2018 | Series A | $4M | - |
Mentions in press and media 5
| Date | Title | Description |
| 21.12.2018 | Term Sheet — Friday, December 21 | 2019 CRYSTAL BALL Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop —- Before we get to your 2019 business predictions, I wanted to share with you some news from Fortune. Chatchava... |
| 20.12.2018 | Kypha Secures $4M Series A Funding | Kypha, a St Louis, MO-based medical diagnostics company, secured $4m in Series A funding. The round was led by Arsenal Capital Management. The company intends to use the funds: to complete integration and expand manufacturing capacity of re... |
| 13.11.2015 | Kypha, startup looking to monitor inflammation quickly and accurately, raises $2.1M | Kypha has previously raised $6 million for development along with $1.5 million in grants. BioGenerator has been a prominent investor in the company, along with Arsenal Capital Management, and Serra Ventures from Champaign, Illinois; Saint L... |
| 24.05.2013 | How St. Louis became a tech town | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! This is a guest post by Aaron Perlut. In spite of... |
| - | Kypha, startup looking to monitor inflammation quickly and accurately, raises $2.1M | Medical device company Kypha has raised $2.1 million in a debt offering to further it’s work in managing inflammation. With just one drop of blood, Kypha’s test works much like a diabetes test. Within just a few minutes, the test assigns a ... |